Ultrafast CT developer Imatron sold another of its U.S. HeartScan coronary artery disease risk assessment centers last month, this one to the University of Pittsburgh Medical Center. The June 17 deal transferred HeartScan-Pittsburgh operations to the
Ultrafast CT developer Imatron sold another of its U.S. HeartScan coronary artery disease risk assessment centers last month, this one to the University of Pittsburgh Medical Center. The June 17 deal transferred HeartScan-Pittsburgh operations to the University of Pittsburghs Cardiovascular Institute, which plans to start a preventive heart care center using Imatrons electron beam CT unit.
With its divestiture of HeartScan-Pittsburgh, South San Francisco, CA-based Imatron comes closer to its goal of focusing its efforts on marketing its ultrafast CT units, according to Lewis Meyer, CEO. The company has been seeking individual buyers for each of its centers since earlier this year, after an initial effort to sell all four centers to one buyer failed.
In February, the company sold its South San Francisco facility to Imaging Technology Group, also of South San Francisco, and a month later found a potential buyer for its Houston and Washington, DC centers in Vital Imaging Companies of Newport Beach, CA (SCAN 3/31/99 and 3/17/99). But the Vital Imaging deal fell through due to lack of financing, so Imatron continues to seek a buyer for the two centers, company executives said.
In other Imatron news, the company sold two Ultrafast CT scanners in late June, one to a German hospital and the other to a San Diego facility. The San Diego sale was financed by GE Capital under the terms of a marketing arrangement between Imatron and GE Medical Systems of Milwaukee (SCAN 6/24/98).
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.